Clinical Trial Update: Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating nivolumab with a CCR2/5 inhibitor or anti-IL-8 in non-small cell lung cancer and hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-IL-8 (anti-IL-8)
• CCR2/5-inhibitor (CCR2/5-inhibitor)
• nivolumab (nivolumab)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Non-small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING